Monday, January 08, 2018 4:32:44 PM
Yes. In addition to the prohibition against insider trading, company stock held by an "affiliate" (e.g. any director or executive officer) of a public company generally must be sold under SEC Rule 144 and Section 16. These restrictions apply whether the stock was acquired by option exercise or purchased in the open market. For details, see the article series on stock sales by executives.
Most companies, as a matter of corporate policy, have blackout periods. Plus, they prohibit their executive officers and directors from buying, selling, pledging, giving, or otherwise transferring any stock of the corporation without first contacting the company's compliance officer. This requirement may also apply to company securities trades by your spouse as well as relatives living in the same household or whose transactions in company stock you control.
Recent CRTG News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 02:51:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/08/2023 06:06:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:43:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:41:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:40:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2023 10:38:33 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 10/31/2023 08:36:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 12:24:21 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM